Activity
(Activity: Sample Activity Plot. For specific information on a given lot, see related technical data sheet.)
COVID 19 Spike RBD (L452R, E484Q) Coronavirus Recombinant Protein | COVID-19 recombinant protein
2019-nCoV Spike protein RBD (L452R, E484Q), HRP conjugated
Synonyms
COVID 19 Spike RBD (L452R; E484Q) Coronavirus; 2019-nCoV Spike protein RBD (L452R; E484Q); HRP conjugated; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike RBD (L452R; 2019-nCoV RBD; SARS-CoV-2 spike RBD; novel coronavirus spike RBD; nCoV spike RBD; Kappa; COVID-19 recombinant protein
Host
CHO cells
Form/Format
Recombinant protein stored in 1 x PBS, pH7.4 and 50% glycerol.
Tag
HIS
Species
Human
Conjugation
HRP conjugated
Preparation and Storage
Store product at -20 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Activity
(Activity: Sample Activity Plot. For specific information on a given lot, see related technical data sheet.)
Activity
(Activity: Sample Activity Plot. For specific information on a given lot, see related technical data sheet.)
Related Product Information for COVID-19 recombinant protein
Recombinant 2019-nCoV Spike protein S1 subunit, RBD (L452R, E484Q)(319-541) was expressed in CHO cells using a C-terminal his tag, and then conjugated to Horse peroxidase (HRP). The gene accession number is MN908947.
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein that recognizes the host ACE2 receptor is a major determinant of viral entry and neutralization, and is the most divergent region (1). L452R mutation has been previously reported in the California variant (B1.429). Mutation at E484 has been detected in the South African (B.1.351), Brazilian (P.1), and NY variants (B.1.526). Lineage B.1.617, also known as the Indian variant carries unique combination of both E484Q and L452R mutations in the RBD of the spike protein. Viruses harboring these individual mutations have reduced susceptibility to both monoclonal antibodies and convalescent plasma (2). As these new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein that recognizes the host ACE2 receptor is a major determinant of viral entry and neutralization, and is the most divergent region (1). L452R mutation has been previously reported in the California variant (B1.429). Mutation at E484 has been detected in the South African (B.1.351), Brazilian (P.1), and NY variants (B.1.526). Lineage B.1.617, also known as the Indian variant carries unique combination of both E484Q and L452R mutations in the RBD of the spike protein. Viruses harboring these individual mutations have reduced susceptibility to both monoclonal antibodies and convalescent plasma (2). As these new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).
Product Categories/Family for COVID-19 recombinant protein
References
1. Lan J, et al: Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235. 2. Verghese M, et al: Identification of a SARS-CoV-2 variant with L452R and E484Q neutralization resistance mutations. J Clin Microbiol. 2021, JCM.00741-21. doi: 10.1128/JCM.00741-21 3. Starr TN, et al: Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. Cell. 2020, 182(5):1295-1310.
NCBI and Uniprot Product Information
Similar Products
Product Notes
The COVID-19 (Catalog #AAA516696) is a Recombinant Protein produced from CHO cells and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "COVID 19 Spike RBD (L452R, E484Q) Coronavirus, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
